Oncology Brothers: Practice-Changing Cancer Discussions
Oncology Brothers
The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap between academic cancer centers and community oncology in the ever-evolving field of hematology & oncology. With a mission to disseminate crucial information to the medical community, this oncology podcast is not for medical advice but rather serves as a beacon for physicians, nurses, trainees, and advanced practice providers (APPs) involved in the care of cancer patients.
Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format.
Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice.
Each episode includes visual presentations so you can follow along within the podcast players and on YouTube @oncbrothers. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities.
If you want to navigate the complexities of your hematology & oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes. For more information, please visit: www.oncbrothers.com, and connect with us on Twitter/X/Instagram/TikTok: @oncbrothers, or email us at info@oncbrothers.com
Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format.
Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice.
Each episode includes visual presentations so you can follow along within the podcast players and on YouTube @oncbrothers. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities.
If you want to navigate the complexities of your hematology & oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes. For more information, please visit: www.oncbrothers.com, and connect with us on Twitter/X/Instagram/TikTok: @oncbrothers, or email us at info@oncbrothers.com
Episodes
Mentioned books
Aug 7, 2025 • 19min
Managing Toxicities of TKIs and HIF-2 inhibitor in Renal Cell Carcinoma (RCC)
Welcome back to the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by world-renowned medical oncologist Dr. Monty Pal from the City of Hope. Together, they dived deep into the management of side effects associated with tyrosine kinase inhibitors (TKIs) and HIF-2 alpha inhibitors used in treating renal cell carcinoma (RCC).
Episode Highlights:
• Understanding TKIs and HIF-2 Inhibitors: A discussion on the available oral treatment options for RCC, including cabozantinib, lenvatinib, and axitinib.
• Dosing Strategies: Insights on starting doses, titration, and the importance of managing side effects without compromising quality of life.
• Common Side Effects: hypertension, diarrhea, fatigue, and how they relate to the class effect of these medications.
• Clinical Pearls: Dr. Pal shared valuable tips on managing toxicities, including the use of treatment breaks and supportive care strategies.
• Second-Line Treatments: A look at tivozanib and belzutifan, including their unique side effects and management strategies.
Join us as we emphasized the importance of maintaining quality of life for patients undergoing treatment for metastatic RCC.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to check out our other episodes for more insights on treatment algorithms, conference highlights, and challenging cases from the community.
Aug 4, 2025 • 26min
Myeloproliferative Neoplasms (MPN) Treatment: Polycythema Vera (PV) & Essential Thrombocythemia (ET)
In this episode of the Oncology Brothers podcast, Drs. Rahul and Rohit Gosain dived deep into the world of myeloproliferative neoplasms (MPNs), focusing specifically on polycythemia vera (PV) and essential thrombocythemia (ET). They are joined by Dr. Andrew Kuykendall, a hematologist from Moffitt Cancer Center, who shared his expertise on the latest treatment paradigms and risk stratification strategies for these conditions.
Key topics discussed included:
• The importance of ruling out secondary causes of erythrocytosis in PV patients.
• The role of JAK2 mutation testing and EPO levels in diagnosis of PV.
• Treatment options for PV, including phlebotomy, hydroxyurea, and interferon, as well as the emerging role of ruxolitinib.
• Risk stratification in ET and the significance of driver mutations like JAK2, CALR, and MPL.
• The management of acquired von Willebrand disease in patients with high platelet counts.
• Insights from Dr. Kuykendall's recent ASCO plenary presentation on the VERIFY Study and the potential of resveratide in PV treatment.
Join us for an informative discussion that highlights the evolving landscape of MPN management and the importance of individualized treatment plans.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to check out our other hematology episodes for more insights into challenging cases and treatment algorithms!
Jul 31, 2025 • 11min
Latest Advances in Tumor-Agnostic Strategies for NTRK Fusion-Positive Cancer
Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain, practicing community oncologists, share their key takeaways from a session on NTRK Fusion Positive Solid Malignancies, they moderated during a satellite event at ASCO 2025 in partnership with Medscape Global Oncology.
Join us as we discuss:
• The prevalence of NTRK fusions in various cancers and why community oncologists should be aware of them.
• The importance of comprehensive next-generation sequencing (NGS) for detecting these fusions across diverse histologies.
• Available treatment options, including first-generation NTRK inhibitors like larotrectinib and entrectinib, and their efficacy in improving overall and progression-free survival.
• Insights into the CNS activity of these treatments and the common side effects patients may experience.
• Special considerations for pediatric patients, including formulation challenges and the potential for re-challenging with NTRK inhibitors.
Don't forget to check out the full accredited enduring program by Medscape Global Oncology linked below, and earn your CME credit.
https://www.medscape.org/viewarticle/1002679?src=acdmpart_onc-brothers_1002679
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
#entrectinib #larotrectinib #repotrectinib
Jul 28, 2025 • 19min
Challenging Cases with Relapsed/Refractory FLT3+ Acute Myeloid Leukemia (AML)
In this episode of the Oncology Brothers podcast, Drs. Rahul and Rohit Gosain dive into the complexities of relapsed refractory Acute Myeloid Leukemia (AML) with FLT3 mutations. Joined by leukemia specialists Dr. Uma Borate from the Ohio State University and Dr. Naval Daver from the MD Anderson Cancer Center, the discussion focused on real-life cases and the current standard of care for patients with FLT3-positive AML.
Key topics included:
• The importance of retesting for FLT3 mutations at the time of relapse
• Treatment paradigms for fit vs. unfit patients
• The role of Gilteritinib and combination therapies in relapsed settings
• Management of side effects, including cytopenias and differentiation syndrome
• Insights into the use of hypomethylating agents and the potential of oral therapies
Whether you're a healthcare professional or someone interested in the latest advancements in cancer care, this episode provides valuable insights into the management of challenging AML cases.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to subscribe for more discussions on the latest in oncology!
Jul 24, 2025 • 25min
Treating Acute Myeloid Leukemia in 2025 - Induction, Consolidation, Transplant, Target Therapies
In this episode of The Oncology Brothers, Drs. Rahul and Rohit Gosain are joined by Dr. Anand Patel, a hematologist and Medical Director of Inpatient Leukemia Service at the University of Chicago. Together, they delved into the complexities of acute myeloid leukemia (AML), one of the most aggressive cancers encountered in clinical practice.
Episode Highlights:
• Understanding the current standard of care for AML, including diagnosis and risk stratification.
• The importance of molecular profiling and how it influences treatment decisions.
• A detailed discussion on induction chemotherapy options, including the classic 7+3 regimen and CPX351 for therapy-related AML.
• Insights into the use of hypomethylating agents combined with venetoclax for patients unfit for intensive chemotherapy.
• The role of targeted therapies in both upfront treatment and relapsed/refractory settings.
• Key considerations for managing side effects, including cytopenias and infections.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
YouTube: https://youtu.be/gbgRbrjHxmQ
Join us as we bridge the gap between academic research and community practice, providing valuable insights for healthcare professionals treating AML patients.
Don't forget to like, subscribe, and check out our other episodes for more discussions on challenging cases and treatment algorithms!
Jul 21, 2025 • 22min
Challenging Cases with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Welcome to this episode of The Oncology Brothers! Drs. Rahul and Rohit Gosain dived into the complexities of relapsed refractory diffuse large B-cell lymphoma (DLBCL) with their new series focused on challenging real-life cases.
In this episode, we are joined by esteemed guests Dr. Carla Casulo from Wilmot Cancer Center and Dr. Tara Graff from Mission Cancer and Blood Center. Together, we explored the current standard of care, including R-CHOP and the role of bi-specific antibodies like epcoritamab and glofitimab.
Key topics covered included:
• When to use bi-specific antibodies and how to manage side effects
• The importance of MRD monitoring in treatment decisions
• Insights on patient management in community oncology settings
• The evolving landscape of treatment options for DLBCL, including CAR-T therapy and clinical trials
We also discuss practical considerations for community oncologists, including the management of cytokine release syndrome (CRS) and the role of immunoglobulin therapy in patients with low IgG levels.
Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode is packed with valuable insights and expert opinions.
YouTube: https://youtu.be/05ieIyAIx_8
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and share your thoughts in the comments! Let us know if there are specific scenarios you'd like us to cover in future episodes.
Jul 17, 2025 • 22min
How to Treat Diffuse Large B-Cell Lymphoma (DLBCL) in 2025
Welcome to the Oncology Brothers podcast! In this episode, Drs. Rohit and Rahul Gosain dive deep into the world of diffuse large B-cell lymphoma (DLBCL), one of the most aggressive yet potentially curable lymphomas. We are joined by Dr. John Leonard, a renowned lymphoma expert from NYU Langone Cancer Center, who shares his insights on the latest data and evolving treatment landscape for DLBCL.
Episode Highlights:
• Understanding the initial workup for DLBCL, including the role of PET-CT and bone marrow biopsies.
• The use of RCHOP and the emerging Pola-R-CHP regimen in Stage 1 and Stage 2 settings.
• Discussion on the treatment options for Stage 3 and Stage 4 disease, including the impact of polatuzumab.
• Insights into managing relapsed/refractory disease and the role of CAR-T therapy.
• The potential shift towards outpatient CAR-T treatments and the nuances between different CAR-T options.
• Exploring bispecific antibodies and their applications in treatment sequencing.
YouTube: https://youtu.be/raGkPnUs9XM
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Join us as we unpack the complexities of DLBCL treatment and share valuable clinical pearls for community settings. Don't forget to subscribe for more episodes on challenging cases and the latest in oncology!
Jul 10, 2025 • 21min
How to Treat Early Stage Non-Small Cell Lung Cancer in 2025
In this episode of the Oncology Brothers podcast, Drs. Rahul and Rohit Gosain are joined by Dr. Deepa Rangachari, a thoracic medical oncologist and fellowship program director at Beth Israel Deaconess Medical Center. Together, they dived deep into the treatment algorithms for early-stage non-small cell lung cancer (NSCLC) with a focus on curative intent.
Key topics discussed include:
• The importance of staging and lymph node evaluation in treatment planning.
• The role of neoadjuvant chemoimmunotherapy and the impact of recent trial data, including the CHECKMATE 816 trial.
• The significance of actionable mutations and the use of targeted therapies like Osimertinib and Alectinib.
• The evolving role of ctDNA in treatment decisions and monitoring.
• Insights into the management of side effects associated with Osimertinib and Alectinib.
• The standard of care for unresectable stage 3 NSCLC, including concurrent chemoradiation and the use of Durvalumab.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Join us for an informative discussion that highlights the latest advancements in lung cancer treatment and the importance of personalized care. Don't forget to check out our other episodes in the lung cancer treatment algorithm series!
Jul 4, 2025 • 18min
ASCO 2025 - GU Cancer Highlights: KEYNOTE-564, AMPLITUDE, ARANOTE, NIAGARA
Welcome to another episode of the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain, both practicing community oncologists, are joined by Dr. Tian Zhang from UT Southwestern to discuss key highlights from the ASCO 2025 annual meeting, focusing on genitourinary (GU) malignancies.
Episode Highlights:
• KEYNOTE-564: discussed 5 years OS data, reinforcing the role of adjuvant pembrolizumab in renal cell carcinoma
• AMPLITUDE: combination of PARP inhibitor niraparib with abiraterone improved progression-free survival in patients with homologous recombination repair mutations in metastatic hormone-sensitive prostate cancer
• ARANOTE: positive quality of life impact when using darolutamide in metastatic hormone-sensitive prostate cancer, which is also FDA approved now
• NIAGARA: the prognostic value of ctDNA in muscle-invasive bladder cancer, emphasizing its implications for treatment strategies
YouTube: https://youtu.be/Rt8HQpdyVY0
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Join us as we break down these important studies and their potential to change clinical practice in oncology. Don't forget to check out our other episodes for more insights into cancer care!
Jun 27, 2025 • 12min
FDA Approval of Telisotuzumab (Teliso-V) in c-MET Overexpression - LUMINOSITY trial
Welcome to another episode of the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Ross Camidge, a leading thoracic medical oncologist from the University of Colorado, to discuss the recent approval of telisotuzumab-vedotin (Teliso-V) for metastatic non-small cell lung cancer (NSCLC) with C-met overexpression, based on the LUMINOSITY trial.
Join us as we explore:
• The mechanism of action of telisotuzumab and its role as an antibody-drug conjugate.
• The prevalence of C-met overexpression in NSCLC and its implications for testing and treatment.
• Key findings from the Luminosity trial, including response rates and study design.
• The importance of C-met testing in clinical practice.
• Management of side effects associated with telisotuzumab, particularly peripheral neuropathy.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
This episode is packed with valuable insights for oncologists and healthcare professionals navigating the evolving landscape of lung cancer treatment. Don't miss out on this informative discussion!
